Enhanced anticancer effect of cetuximab combined with stabilized silver ion solution in EGFR-positive lung cancer cells
dc.contributor.author | Ozkan, Aysun | |
dc.contributor.author | Erdogan, Ayse | |
dc.contributor.author | Ozkan, Odul | |
dc.contributor.author | Manguoglu, Esra | |
dc.contributor.author | Kiraz, Nadir | |
dc.date.accessioned | 2020-11-02T07:17:07Z | |
dc.date.available | 2020-11-02T07:17:07Z | |
dc.date.issued | 2019 | |
dc.description.abstract | Background: Cytotoxic, antiproliferative, cell cycle inhibitive, oxidative and apoptotic effects of cetuximab [antibody for epidermal growth factor receptor (EGFR)] alone and together with stabilized silver ion solution (St-Ag) on P-H1299, R-H1299, A-431 and A-549 cells were investigated. Materials and methods: Cytotoxic effects of cetuximab alone and together with St-Ag on cells were determined by Cell Titer-Blue((R)) Cell Viability and Lactate Dehydrogenase Activity tests. Cell cycle distributions and apoptosis were detected by reverse transcription polymerase chain reaction (RT-PCR). Results: St-Ag enhanced cetuximab cytotoxic effect on all cells. LDH activity, as a result of cell death, was found the highest level at treatment of cetuximab with St-Ag in all cells. Both treatment increased caspase-3/7 activity which is apoptotic enzyme was found higher in A-549 cells than other cells. Also, treatment of cetuximab with St-Ag caused increasing Bax/Bcl-2 ratio in all cells. Cetuximab with St-Ag treatment increased glutathione peroxidase activity in all cells generating oxidative stress. Proliferating Cell Nuclear Antigen (PCNA), topoisomerase II-alpha (except R-H1299), cyclin D1 and D2 genes expression were decreased in all cells which explain the cell cycle inhibition effect. Conclusion: These findings suggest that treatment of cetuximab combined with St-Ag exhibit more carcinogenesis reducing potential than cetuximab alone. | en_US |
dc.identifier.endpage | 437 | en_US |
dc.identifier.issn | 0250-4685 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.scopus | 2-s2.0-85073567897 | en_US |
dc.identifier.startpage | 426 | en_US |
dc.identifier.uri | http://hdl.handle.net/11727/4985 | |
dc.identifier.volume | 44 | en_US |
dc.identifier.wos | 000489303900003 | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1515/tjb-2018-0033 | en_US |
dc.relation.journal | TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Cetuximab | en_US |
dc.subject | stabilized silver solution | en_US |
dc.subject | apoptosis | en_US |
dc.subject | lung cancer | en_US |
dc.subject | combined treatment | en_US |
dc.title | Enhanced anticancer effect of cetuximab combined with stabilized silver ion solution in EGFR-positive lung cancer cells | en_US |
dc.type | article | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: